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Introduction: G-CSF Filgrastim is widely used for the
mobilization of CD34+ HSC. The experience with biosimilar
G-CSF agents is limited. We initiated a prospective study
assessing Tevagrastim (biosimilar Filgrastim XMO2) for
mobilization of CD34+ PB HSC in MRD for alloSCT in 24 pts
with AML/MDS (NCT01542944).
Materials and methods: The study was approved by the
National Regulatory Authorities and both patients and do-
nors signed an informed consent. The donors, median age 46
years (range, 25e64), F- 14; M- 10 received Tevagrastim (10
mg/kg) BW s.c. BID for 4 days. On the morning of the 5th day
they underwent conventional leukapheresis. The target
yields of CD34 cell was 5  106 CD34+ cells/kg BM of the
recipient. The conditioning was myeloablative Bu/Cy (n¼10),
reduced toxicity Flu/Treo (n¼7), Flu/Bu4 (n¼3) or RIC Flu/
Bu2 (n¼4).
Results: Efﬁcacy: 77-1982  106 (median 749  106) CD34+
were collected. The number of CD34+ cell per kg BW of the
pts was 0.93-35.4  106 (median 10.2  106). Collections
contained 144-709  108 (median 299  108) CD3+ T-cells,
1.74-11.6 108 (median 4.4 108) per kg BW of the pts and
0.3-11.2x107/kg (median 2.3x107/kg) CD3- CD56+ CD16+ NK
cells. The mean number of leukapheresis procedures was 1.3.
Engraftment was: ANC >0.5 109/L and >1 109/L within a
median of 13 days (range, 10e21) and 13.5 days (range,
10e22), respectively. PLT reached counts of >20 109/L and
>50 109/L within a median of 16 (range, 12e33) and 17
(range, 12e33) days, respectively. The median days of isola-
tion was 10 (range, 6-21). The median number of PC and PLT
transfusions was 5 (range, 2-20) and 21 (range, 0-180),
respectively. 20/24 (83.3%) pts showed full donor chimerism
at 1 month after transplantation, respectively.
Safety: 12/24 donors reported transient arthralgias and 2
developed ﬂu-like syndrome. The main side effects were
mucositis (n-15, grade II -9, grade III-IV- 6), infections (n-20)Figure 1. Representative dot plot showing the exprand ﬂuid retention (n-8). One pt suffered from VOD (Grade-I)
and 5 pts developed aGVHD (grade II-III) which responded to
conventional therapy. In total TRM was 1/24 at d 100. Total 5
pts died from leukemia progression during median 7 (range,
1-16) months; 2 of them died before d 100. 4 pts suffered
from chronic, mild GVHD.
Conclusions: Our study with 24 AML/MDS pts, indicates
that the G-CSF biosimilar XM02, Tevagrastim is safe and
efﬁcient for stem cells mobilization in MRD. The CD34 yield
and post transplantation engraftment are similar to those
achieved with the human recombinant G-CSF Filgrastim.
We have not seen signiﬁcant differences in the graft CD34+ ,
CD3+ T and CD16+ NK cell count, the number of leukaphe-
resis procedures and the regeneration of WBC, neutrophils
and PLTs in comparison with our historical controls. All
patients promptly engrafted, and the donors developed only
expected side effects. Neither graft rejection nor side effects
occurred more frequently than expected from the standard
G-CSF.401
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Introduction: We previously reported that cord blood T-
cells (CBT), obtained from <3% of cord blood graft can be
expanded, and primed against (lymphoid and myeloid leu-
kemia cell lines in the presence of IL12, IL7 and IL15 (Cancer
Research, 2010; 70(13): 5249). Recently, we demonstrated
that IL15 alone can support the priming and expansion of
CTL.
Hypothesis: CD137 (4-1BB) is a member of the TNFR- family,
expressed on activated T cells, which augment the survival
and proliferation. Here we tested the hypothesis that de-
novo CD137 expression may identify leukemia-speciﬁc CTL.
Methods: IM9-speciﬁc CTL was generated from pre-
expanded CBT cells using weekly stimulations with irradi-
ated targets and IL15. After 3 weeks, cytotoxicity was tested,
re-stimulated to sort CD137 expressing cells (BD Biosciences)
and were re-tested for cytotoxicity and TCRb CDR3 spec-
tratyping was done to identify their clonality. RT2 proﬁlerTM
PCR array human Th1 & Th2 responses (SABiosciences) were
employed to identify the differential gene expression.ession of CD137 on CTL before and after sort
